Notifications
Clear all
Topic starter
26/08/2020 10:36 am
hot off the press from the worlds leading medical journal (bear in mind this study was in older men):
Adverse Events Associated with Testosterone Administration
ABSTRACT
Background Testosterone supplementation has been shown to increase muscle mass and strength in healthy older men. The safety and efficacy of testosterone treatment in older men who have limitations in mobility have not been studied.
Methods Community-dwelling men, 65 years of age or older, with limitations in mobility and a total serum testosterone level of 100 to 350 ng per deciliter (3.5 to 12.1 nmol per liter) or a free serum testosterone level of less than 50 pg per milliliter (173 pmol per liter) were randomly assigned to receive placebo gel or testosterone gel, to be applied daily for 6 months. Adverse events were categorized with the use of the Medical Dictionary for Regulatory Activities classification. The data and safety monitoring board recommended that the trial be discontinued early because there was a significantly higher rate of adverse cardiovascular events in the testosterone group than in the placebo group.
Results A total of 209 men (mean age, 74 years) were enrolled at the time the trial was terminated. At baseline, there was a high prevalence of hypertension, diabetes, hyperlipidemia, and obesity among the participants. During the course of the study, the testosterone group had higher rates of cardiac, respiratory, and dermatologic events than did the placebo group. A total of 23 subjects in the testosterone group, as compared with 5 in the placebo group, had cardiovascular-related adverse events. The relative risk of a cardiovascular-related adverse event remained constant throughout the 6-month treatment period. As compared with the placebo group, the testosterone group had significantly greater improvements in leg-press and chest-press strength and in stair climbing while carrying a load.
Conclusions In this population of older men with limitations in mobility and a high prevalence of chronic disease, the application of a testosterone gel was associated with an increased risk of cardiovascular adverse events. The small size of the trial and the unique population prevent broader inferences from being made about the safety of testosterone therapy. (ClinicalTrials.gov number, NCT00240981
26/08/2020 10:57 am
this was posted the other day. not sure it's worth repeating.!
And we'll collect the moments one by one. I guess that's how the future's done. Feist, "Mushaboom", 2005
Topic starter
26/08/2020 11:20 am
oops, BM needs to check into CEM more often lol!
thou it is the worlds top medical journal, so worthy of a repeat post
26/08/2020 11:48 am
is also not worth reading! sheesh, lets see, 74 yo men (on average) at deaths door are given test and asked to work out. no mention of administration of ace's or arbs just thatt they all suffer from chronic debilitating disease, i mean what kind of research are these folks getting paid to do....
jb
26/08/2020 12:15 pm
since it is the NEJM, it is noteworthy. I just wonder what is up in the field of medicine and perhaps politics on this issue? However, I found this study riddled with some of the same flaws as the WHO and HERS studies for women-----as JB noted.
The real danger here is that the flaws are apparent if you read the studies. However, if you just read the conclusions, you can be mislead. Unfortunately, there are too many docs who will do just that.
And we'll collect the moments one by one. I guess that's how the future's done. Feist, "Mushaboom", 2005